Goldman Sachs Group Inc. boosted its stake in shares of Akorn, Inc. (NASDAQ:AKRX) by 5.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,282,064 shares of the company’s stock after buying an additional 71,158 shares during the period. Goldman Sachs Group Inc. owned about 1.03% of Akorn worth $30,872,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of AKRX. NEXT Financial Group Inc raised its position in Akorn by 990.9% in the first quarter. NEXT Financial Group Inc now owns 3,000 shares of the company’s stock valued at $100,000 after buying an additional 2,725 shares during the last quarter. Meadow Creek Investment Management LLC raised its position in Akorn by 8.3% in the first quarter. Meadow Creek Investment Management LLC now owns 4,368 shares of the company’s stock valued at $105,000 after buying an additional 336 shares during the last quarter. Glen Harbor Capital Management LLC raised its position in Akorn by 8.3% in the first quarter. Glen Harbor Capital Management LLC now owns 5,304 shares of the company’s stock valued at $128,000 after buying an additional 408 shares during the last quarter. Private Advisor Group LLC purchased a new position in Akorn during the first quarter valued at $164,000. Finally, LS Investment Advisors LLC raised its position in Akorn by 21.8% in the first quarter. LS Investment Advisors LLC now owns 7,850 shares of the company’s stock valued at $189,000 after buying an additional 1,407 shares during the last quarter. Institutional investors own 75.04% of the company’s stock.

Akorn, Inc. (AKRX) traded down 0.09% during midday trading on Thursday, reaching $33.45. 2,939,444 shares of the company’s stock were exchanged. Akorn, Inc. has a 52 week low of $17.61 and a 52 week high of $35.40. The stock’s 50 day moving average is $33.55 and its 200 day moving average is $28.49. The firm has a market capitalization of $4.18 billion, a P/E ratio of 33.79 and a beta of 1.37.

WARNING: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/03/akorn-inc-nasdaqakrx-position-increased-by-goldman-sachs-group-inc-updated-updated-updated.html.

Several research firms have weighed in on AKRX. TheStreet upgraded shares of Akorn from a “c+” rating to a “b-” rating in a report on Thursday, April 20th. Royal Bank Of Canada set a $34.00 price objective on shares of Akorn and gave the stock a “hold” rating in a report on Saturday, May 27th. William Blair lowered shares of Akorn from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 25th. Jefferies Group LLC lowered shares of Akorn from a “buy” rating to a “hold” rating and upped their price objective for the stock from $24.00 to $34.00 in a report on Tuesday, April 25th. Finally, Craig Hallum lowered shares of Akorn from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $30.20.

About Akorn

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Institutional Ownership by Quarter for Akorn (NASDAQ:AKRX)

Receive News & Stock Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related stocks with our FREE daily email newsletter.